Fractyl Health, Inc.
GUTSHealthcare|Biotechnology|US
$0.93
+0.03 (+3.80%)
DCF Value
$1.44
Cash / Share
$3.57
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06092476 Trial to Evaluate Efficacy+Safety of Revita DMR Treatment Paradigm 1 and Retreatment in Type 2 Diabetes Patients | Diabetes Mellitus, Type 2 | N/A | Active | 18 | RCT, Double-blind | — |
| NCT06484114 Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide | Obesity, Weight Change Trajectory | N/A | Active | 315 | RCT, Double-blind | — |
| NCT02879383 Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D) | Diabetes Mellitus, Type 2, Noninsulin-Dependent Diabetes Mellitus | N/A | Completed | 109 | RCT, Double-blind | — |
| NCT01927562 Initial Clinical Evaluation of an Endoscopic Therapy for Type 2 Diabetes | Type II Diabetes | N/A | Completed | 57 | Open-label | — |
| NCT06256497 A Prospective Study to Evaluate Revita DMR Post Market Pilot Clinical Follow-Up Registry in Patient With Type 2 Diabetes | Diabetes Mellitus, Type 2 | SUSPENDED | 100 | — | — | |
| NCT03536650 Effect of DMR in the Treatment of NASH | NASH - Nonalcoholic Steatohepatitis | N/A | Completed | 14 | Open-label | — |
| NCT03653091 Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes | Type 2 Diabetes | N/A | Completed | 9 | RCT, Double-blind | — |
| NCT02413567 Evaluation of Duodenal Mucosal Resurfacing in Subjects With Type 2 Diabetes | Diabetes Mellitus, Type 2, Diabetes Mellitus | N/A | Completed | 60 | Open-label | — |
| NCT04419779 Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes | Type 2 Diabetes | N/A | SUSPENDED | 320 | RCT, Double-blind | — |